TriSalus Life Sciences, Inc. (TLSI)

5.85 -0.29 (-4.72%) USD  |  NASDAQ  |  Jan 09, 14:59
More

TriSalus Life Sciences Research and Development Expense (Quarterly): 5.176M for Sept. 30, 2025

Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for TLSI.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
ICU Medical, Inc. 21.25M
Perspective Therapeutics, Inc. 19.56M
InfuSystem Holdings, Inc. --
Xtant Medical Holdings, Inc. 0.634M
VolitionRX Ltd. 2.022M